Alexander KarpAlexander Karp earned $1B in 2024

In 2023, Mark A. Velleca, M.D., Ph.D. earned $244.28K in total compensation at Black Diamond Therapeutics, Inc., primarily from $180.33K salary. Most recently sold 60,000 shares in Aug 2023. Currently holds stock worth $335.40K. Has donated $7.15K in stock to charitable causes. 2+ years at the helm of Black Diamond Therapeutics, Inc..

Compensation History

Annual executive compensation data for Mark A. Velleca, M.D., Ph.D., including salary, bonuses, and stock awards.

Year

2023

Total Compensation

$244.28K

Salary

$180.33K

Bonus

$0.00

Other

$63.95K

Salary

$180.33K

Board Justification

The compensation philosophy is based on a pay-for-performance model, aligning executive compensation with company performance and market benchmarks.

Bonus

$0.00

Board Justification

No bonus was awarded for 2023 as the CEO position was held for part of the year only.

Other Compensation

$63.95K

Board Justification

This includes a 401(k) matching contribution and a $6,000 annual stipend for personal expenses.

Restricted Stock

$0.000 N/A

Board Justification

No stock awards vested in 2023 as the stock options granted were not specified to have vested during the year.

Performance Metrics

Performance metrics for determining compensation include corporate goals related to financial and operational measures.

B

Mark A. Velleca, M.D., Ph.D.

CEO of Black Diamond Therapeutics, Inc.

Education

M.D. and Ph.D. from Washington University in St. Louis

Field of Expertise

Healthcare & Life Sciences - Biotechnology

Sector of Economy

Healthcare

Born

January 1, 1973 - 52 years ago

CEO of Black Diamond Therapeutics, Inc. for

2 years 2 months (Sep 2023 - Present)

Previous Experience

Former CEO of G1 Therapeutics, Inc.

Holdings

Track Mark A. Velleca, M.D., Ph.D.'s stock holdings and portfolio value over time.

Total Stock Sold

$8.92M

GTHX

$8.92M

456,040 GTHX shares

What if they kept their stock?

If Mark A. Velleca, M.D., Ph.D. didn't sell their stock, today they would have:
Extra GTHX456,040 shares worth $3.26M.
This is -63.44% and $5.66M less than what they got when they sold the stock.

Charitable Transactions

GTHX

1,000 shares

GTHX

Recent Charitable Transactions

GTHX

1,000 shares

GTHX

Jul 16, 2018

Charity

Insider Trading

Mark A. Velleca, M.D., Ph.D.'s recent stock transactions, purchases, and sales filed with the SEC.

GTHX

$120.56K

GTHX at $2.01/share

Aug 8, 2023

Sale

GTHX

$175.49K

GTHX at $11.70/share

Oct 18, 2022

Sale

GTHX

$270.04K

GTHX at $13.50/share

Sep 20, 2022

Sale

GTHX

$1.01M

GTHX at $12.64/share

Aug 16, 2022

Sale

GTHX

$570.26K

GTHX at $19.01/share

Jul 13, 2021

Sale

GTHX

$659.02K

GTHX at $21.97/share

Jun 15, 2021

Sale

GTHX

$597.10K

GTHX at $19.90/share

May 11, 2021

Sale

GTHX

$733.77K

GTHX at $24.46/share

Apr 13, 2021

Sale

GTHX

$983.48K

GTHX at $31.68/share

Feb 16, 2021

Sale

GTHX

$630.29K

GTHX at $21.01/share

Jan 19, 2021

Sale

Rivals

Compare Mark A. Velleca, M.D., Ph.D. with competitor CEOs and industry peers.